Skip to main content

Esophagitis

3
Pipeline Programs
6
Companies
8
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
267%
Small Molecule
133%
+ 5 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
3 programs
1
1
pantoprazolePhase 4Small Molecule1 trial
Full dose Pantoprazole plus matching placeboPhase 21 trial
Does not applyN/A2 trials
Active Trials
NCT01213823Terminated536Est. May 2011
NCT01322633Completed61,864Est. Mar 2013
NCT04821310Terminated43Est. Dec 2025
+1 more trials
Sandoz
SandozAustria - Kundl
1 program
1
omalizumabPhase 2Monoclonal Antibody
Ortho Development
1 program
Comparison of Acid Reflux at Two Levels in the Esophagus Using the BRAVO CapsuleN/A1 trial
Active Trials
NCT00579410Completed85Est. Oct 2009
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
Eosinophilic Esophagitis DatabankN/A1 trial
Active Trials
NCT01323803Completed709Est. Feb 2016
Providence Therapeutics
1 program
Whole Food InterventionPHASE_1_21 trial
Active Trials
NCT02575391Terminated7Est. Sep 2012
Novartis
NovartisBASEL, Switzerland
1 program
omalizumabPHASE_2Monoclonal Antibody1 trial
Active Trials
NCT00123630Completed30Est. Jan 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Pfizerpantoprazole
PfizerFull dose Pantoprazole plus matching placebo
Novartisomalizumab
Providence TherapeuticsWhole Food Intervention
Allergy TherapeuticsEosinophilic Esophagitis Databank
PfizerDoes not apply
PfizerDoes not apply
Ortho DevelopmentComparison of Acid Reflux at Two Levels in the Esophagus Using the BRAVO Capsule

Clinical Trials (8)

Total enrollment: 63,294 patients across 8 trials

NCT00133770Pfizerpantoprazole

Intravenous (IV) Pantoprazole in Erosive Esophagitis

Start: Jul 2004Est. completion: Mar 200720 patients
Phase 4Completed
NCT04821310PfizerFull dose Pantoprazole plus matching placebo

Protonix Treatment of Maintenance of Healing in Pediatric Participants Aged 1-11 Years and 12-17 Years

Start: Jan 2022Est. completion: Dec 202543 patients
Phase 2Terminated
NCT00123630Novartisomalizumab

A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab

Start: Nov 2005Est. completion: Jan 201030 patients
Phase 2Completed
NCT02575391Providence TherapeuticsWhole Food Intervention

The Effects of Whole Food Intervention on Mucositis in Patients Treated for Thoracic Cancer

Start: Oct 2009Est. completion: Sep 20127 patients
Phase 1/2Terminated
NCT01323803Allergy TherapeuticsEosinophilic Esophagitis Databank

Eosinophilic Esophagitis Databank

Start: Apr 2011Est. completion: Feb 2016709 patients
N/ACompleted
NCT01213823PfizerDoes not apply

Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins

Start: Sep 2008Est. completion: May 2011536 patients
N/ATerminated
NCT01322633PfizerDoes not apply

Risk of Cancer Among Pantoprazole Users

Start: Jul 2004Est. completion: Mar 201361,864 patients
N/ACompleted
NCT00579410Ortho DevelopmentComparison of Acid Reflux at Two Levels in the Esophagus Using the BRAVO Capsule

Comparison of Acid Reflux at Two Levels in the Esophagus Using the BRAVO Capsule

Start: May 2004Est. completion: Oct 200985 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.